Maravai LifeSciences Holdings Inc. Class A Common Stock vs Vishay Intertechnology Inc. Common Stock — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Vishay Intertechnology Inc. Common Stock trades at $28.25 (market cap $4.87B). The key difference: Vishay Intertechnology Inc. Common Stock is far larger — about 5× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Vishay Intertechnology Inc. Common Stock pays a 1.26% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Vishay Intertechnology Inc. Common Stock for 6 Days on average.
| MRVI | VSH | |
|---|---|---|
Market Cap | $972.90M | $4.87B |
Volume | 4,325,710 | 2,805,188 |
Sector | Health | Technology |
52-Week High | $9.00 | $64.90 |
52-Week Low | $2.83 | $11.82 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $1.08B | $4.67B |
Dividend Yield | — | 1.26% |
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Vishay Intertechnology (VSH) trades at $31.76, down 0.84% with bearish technical signals despite recent earnings beats. The stock shows mixed fundamentals with a high P/E ratio of 158.8 but improving profitability trends, with net income projected to turn positive in 2026. Recent news highlights the company's focus on EV and AI infrastructure solutions, positioning it for growth in key technology markets.
While analyst consensus remains positive with a $43 price target, investors face valuation concerns and execution risks. The technical outlook suggests near-term pressure, but long-term growth potential exists if the company can capitalize on automotive and AI semiconductor demand while improving profit margins from current low levels.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →Vishay Intertechnology manufactures discrete semiconductors and passive electronic components. Its products include diodes, MOSFETs, resistors, capacitors, and sensors.
Read more on VSH →